The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01A | Cardiac glycosides | |
| 4 | C01AA | Digitalis glycosides | |
| 5 | C01AA05 | Digoxin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.25 mg |
| PAREN - Parenteral | 0.25 mg |
| Active Ingredient | Description | |
|---|---|---|
| Digoxin |
Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DIGOXIN Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| DIGOXIN Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| Lanoxin 125 Tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| LANOXIN Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| LANOXIN Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
